Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

NCT07572136 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

57

Enrollment

NIH

Sponsor class

Conditions

B-All
Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: TSLPR-CART
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

National Cancer Institute (NCI)